STOCK TITAN

BioAtla (BCAB) DEF 14A Filings

BCAB OTC

Here are the DEF 14A proxy statements from BioAtla Inc (BCAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.

Rhea-AI Summary

BioAtla, Inc. is asking shareholders to vote at its 2026 Annual Meeting, which will be held virtually on July 16, 2026 at 8:00 a.m. Pacific Time via live webcast. Holders of common stock as of May 18, 2026 are entitled to vote.

Shareholders will elect two Class III directors, Jay M. Short and Edward Williams, ratify Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and cast a non-binding advisory vote on 2025 executive compensation. The board recommends voting “FOR” all three proposals.

The company notes that a 50-for-1 share consolidation became effective on April 6, 2026, and all share and per-share figures have been adjusted. The board highlights its committee structure, director independence, diversity profile, and a pay-for-performance philosophy with stock ownership guidelines for directors and executives.

Rhea-AI Summary

BioAtla, Inc. is asking stockholders to approve three proposals at a virtual special meeting on December 30, 2025. The first would approve the potential issuance of 20% or more of the common stock outstanding as of November 20, 2025 under Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement with Yorkville and Anson funds, allowing sales below Nasdaq’s minimum price beyond an Exchange Cap of 11,752,538 shares, which equals 19.99% of outstanding shares on that date. These arrangements include a $15.0 million equity purchase commitment and a $7.5 million pre-paid advance, partly already converted into 479,294 shares, plus a 243,428‑share commitment fee.

The second proposal would amend the charter to permit a reverse stock split of common stock at a ratio between 1‑for‑5 and 1‑for‑20 any time before June 30, 2026, at the board’s discretion. The goal is to raise the share price above Nasdaq’s $1.00 minimum bid and regain compliance after the stock traded below that level for more than 30 consecutive trading days, with a compliance deadline of February 2, 2026. The split would not change authorized share counts but would increase authorized, unissued shares and may affect liquidity, create odd lots, and potentially reduce market capitalization.

The third proposal would allow adjournment of the meeting for up to 30 days to solicit additional proxies if there are insufficient votes to pass the stock issuance or reverse stock split proposals. Failure to approve the stock issuance could force BioAtla to repay the pre-paid advances in cash, plus a 10% premium, which the company says could strain working capital and push it toward less favorable, potentially more dilutive financing alternatives.